April 25, 2022 -- Bruker debuted new multiplex polymerase chain reaction (PCR) infectious disease assays and upgrades to its existing matrix-assisted laser desorption/ionization (MALDI) Biotyper platform at the annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMIB).
The FluoroType Mycobacteria PCR assay launches on the FluoroCycler XT thermocycler and uses the company's LiquidArray technology to differentiate 31 nontuberculous mycobacteria and the M. tuberculosis complex from cultures in a single test.The FluoroType PCR assay for detecting sexually transmitted infections (STIs) also uses the LiquidArray technology; the assay detects nine targets from seven sexually transmitted pathogens using a single test. The assay detects two independent genes for both Neisseria gonorrhoea and Chlamydia trachomatis. The STI assay is validated on the GenoXtract extraction system and the Fluorocycler XT thermocycler.
Bruker also showcased its new MBT Compass HT in vitro diagnostics (IVD) software at ECCMIB 2022. The application provides higher sample throughput for the MALDI Biotyper with a system time-to-result of ~5 minutes for 96 sample spots. It identifies up to 600 samples/hour/instrument.
Finally, the firm announced it has added 393 new species to its IVD CE-labeled MALDI Biotyper Reference Libraries, providing nearly universal identification capabilities for 4,381 species.
None of the featured products are available for sale yet in the U.S.
Copyright © 2022 scienceboard.net